Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: a double-blind clinical trial | Zendy

Saeed Shoja Shafti | Zendy; Hamid Kaviani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: a double-blind clinical trial

Author(s) -

Saeed Shoja Shafti,

Hamid Kaviani

Publication year - 2014

Publication title -

therapeutic advances in psychopharmacology

Language(s) - English

Resource type - Journals

eISSN - 2045-1261

pISSN - 2045-1253

DOI - 10.1177/2045125314560739

Subject(s) - aripiprazole , quetiapine , fluvoxamine , clinical global impression , clinical trial , medicine , psychology , psychiatry , schizophrenia (object oriented programming) , serotonin , placebo , fluoxetine , receptor , alternative medicine , pathology

Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research